Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China

Loading...
Loading...
  • Milestone Pharmaceuticals Inc MIST hit a major snag last March when its investigational etripamil nasal spray for episodes of rapid heart rate missed the primary endpoint.
  • A year later, it’s touting new data on its secondary endpoints and a partnership with Ji Xing Pharmaceuticals to develop the candidate in China for paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions.
  • Ji Xing is paying $15 million upfront and making a $5 million equity investment for the rights to develop and commercialize etripamil, a fast-acting calcium channel blocker, in Greater China.
  • The agreement involves milestone payments of up to $107.5 million.
  • At ACC 2021, Milestone said etripamil had higher scores than placebo related to relief of specific symptoms associated with PSVT, including rapid pulse (p=0.002), palpitations (p<0.001), shortness of breath (p=0.008), dizziness (p=0.012), and anxiety (p=0.006).
  • In addition, a 51% reduction (p=0.051) in need for an emergency room (ER) visit and a 47% prolongation (p<0.05) in time to ER intervention was observed in patients who received etripamil versus placebo.
  • Price Action: MIST shares are down 0.9% at $5.50 during the market session on the last check Monday.
Posted In: BiotechNewsHealth CareContractsFDAGeneralBriefsCardiovascular disease
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...